FDA Approves New Rheumatoid Arthritis Medication for People Who Haven't Responded to Standard Treatment

The U.S. FDA has recently approved upadacitinib, an oral medication for adults with mild to severe rheumatoid arthritis (RA) that is not being well-controlled by methotrexate.

Rinvoq is the brand name for upadacitinib, a Janus kinase (JAK) inhibitor for the treatment rheumatoid arthritis (RA) in adults who have had an inadequate response to methotrexate. It is a DMARD, administered orally and manufactered by AbbVie.

Read full article ↗